{
    "Clinical Trial ID": "NCT00005908",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine",
        "  Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.",
        "INTERVENTION 2: ",
        "  Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine",
        "  Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 orally twice daily day 2-15"
    ],
    "Eligibility": [
        "INCLUSION CRITERIA:",
        "  Stage II or III breast cancer with a tumor size of greater than 2 cm. Patients with a previous biopsy are eligible provided adequate tumor tissue remains for biopsy in this study.",
        "  At least 18 years of age.",
        "  Adequate hematopoietic function as defined by absolute neutrophil count greater than 1200/mm^3 and platelet count greater than 100,000/mm^3.",
        "  Adequate renal function as defined by creatinine less than 1.6 mg/dL.",
        "  Adequate hepatic function as defined by total (T.) bilirubin less than 1.4 mg/dL and serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) less than 1.5 times the upper limit of normal and alkaline phosphatase less than 2.5 times upper limit of normal",
        "  Zubrod Performance status 0-2.",
        "EXCLUSION CRITERIA:",
        "  Medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude chemotherapy administration. Patients may be evaluated by psychiatry or medical subspecialties as appropriate.",
        "  Pregnant or lactating women",
        "  Known bleeding disorders",
        "  Hypersensitivity to Tween 80 (Polysorbate)",
        "  Cardiac ejection fraction below normal limits, myocardial infarction within the past 12 months, or symptomatic arrhythmia requiring medical intervention.",
        "  Prior chemotherapy or hormonal therapy for breast cancer. Patients treated with hormonal chemoprevention (tamoxifen or raloxifene) will be eligible.",
        "  Active malignancy diagnosed within the last 5 years. (Cervical cancer or non-melanomatous skin cancer that has been treated with curative intent will be eligible)."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Adverse Events",
        "  Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.",
        "  Time frame: 6 years",
        "Results 1: ",
        "  Arm/Group Title: Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine",
        "  Arm/Group Description: Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.",
        "  Overall Number of Participants Analyzed: 9",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  9",
        "Results 2: ",
        "  Arm/Group Title: Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine",
        "  Arm/Group Description: Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 orally twice daily day 2-15",
        "  Overall Number of Participants Analyzed: 20",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  20"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 29/30 (96.67%)",
        "  Febrile neutropenia  [1]3/30 (10.00%)",
        "  Lymphatics 1/30 (3.33%)",
        "  Diarrhea (without colostomy) 5/30 (16.67%)",
        "  Abdominal pain or cramping 2/30 (6.67%)",
        "  Colitis 1/30 (3.33%)",
        "  Dehydration 1/30 (3.33%)",
        "  Nausea 1/30 (3.33%)",
        "  Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%)",
        "  Vomiting 1/30 (3.33%)",
        "Adverse Events 2:",
        "   "
    ]
}